SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société SWEDISH ORPHAN BIOVITRUM AB (PUBL)
05/10Bulletin from Swedish Orphan Biovitrum (Sobi®)'s Annual General Meeting (AGM)
AQ
04/28Sobi publishes Q1 2022 report
AQ
04/20INVITATION : Sobi's Q1 2022 report
AQ
04/06Swedish Orphan Biovitrum AB - Annual and Sustainability Report 2021
AQ
04/06Swedish Orphan Biovitrum AB - Notice of Annual General Meeting in Swedish Orphan Biovit..
AQ
04/05Sobi publishes 2021 Annual and Sustainability Report
AQ
04/05Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AQ
03/23Sobi to cease ReFacto manufacturing in the first quarter of 2024
AQ
03/18Gamifant approved in China for the treatment of primary haemophagocytic lymphohistiocyt..
AQ
03/09Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophi..
AQ
02/25Gamifant (emapalumab) recommended for approval in China for treatment of primary haemop..
AQ
02/11Swedish Orphan Biovitrum - Sobi publishes Q4 and FY 2021 report
AQ
02/10Sobi publishes Q4 and FY 2021 report
AQ
02/03INVITATION : Sobi's Q4 and FY 2021 report
AQ
02/02Sobi to present new data at EAHAD 2022
AQ
2021Kineret® (anakinra) receives positive opinion from the CHMP for treatment of patients w..
AQ
2021Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
AQ
2021Aspaveli®/Empaveli™ (pegcetacoplan) demonstrated sustained normalisation of clini..
AQ
2021Sobi continues the R&D transformation - Anders Ullman appointed new Head of R&D
AQ
2021Statement by the Board of Directors in relation to the withdrawal of the public cash of..
AQ
2021Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study..
AQ
2021Sobi to present new data at the ASH 2021 Annual Meeting
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the third quarter 2021
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the third quarter 2021
AQ
2021SWEDISH ORPHAN BIOVITRUM : Aspaveli® (pegcetacoplan) receives positive CHMP opinion for tr..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi announces preliminary headline numbers for the third quart..
AQ
2021SWEDISH ORPHAN BIOVITRUM : New number of shares and votes in Swedish Orphan Biovitrum AB (..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Nature Medicine publishes positive phase 3 anakinra study resul..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Nature Medicine publishes phase 3 anakinra study results in pat..
AQ
2021INVESTOR : supports Agnafit Bidco's bid for Sobi
AQ
2021SWEDISH ORPHAN BIOVITRUM : Statement by the Board of Directors of Swedish Orphan Biovitrum..
AQ
2021OASMIA PHARMACEUTICAL : strengthens internal capabilities with the appointments of Head of..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Board of directors exercises authorisation for repurchase of sh..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the second quarter 2021
AQ
2021SWEDISH ORPHAN BIOVITRUM : The Board of directors exercises authorisation for repurchase o..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q2 2021 results
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi to present data at the ISTH 2021 within rare haematology d..
AQ
2021SOBI AT EHA VIRTUAL CONGRESS 2021 : focus on results in PNH and treatment for ITP
AQ
2021SWEDISH ORPHAN BIOVITRUM : Positive top-line results from the phase 3 PRINCE study of pegc..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Early use of anakinra reduces risk of mortality for patients wi..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Bulletin from Swedish Orphan Biovitrum's ("Sobi") Annual Genera..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the first quarter 2021
AQ
2021SOBI AND HELLENIC INSTITUTE FOR THE : anakinra improved overall clinical outcomes by 64% ..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q1 2021 results
AQ
2021SWEDISH ORPHAN BIOVITRUM : First patient dosed in phase 3 XTEND-Kids study with efanesocto..
AQ
2021IRLAB's nomination committee proposes Martin Nicklasson as new board member and provide..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi™ publishes 2020 Annual and Sustainability Report
AQ
2021SWEDISH ORPHAN BIOVITRUM : Notice of Annual General Meeting in Swedish Orphan Biovitrum AB..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Evaluation of haemophilia A treatment options shows favourable ..
AQ
2021APELLIS PHARMACEUTICALS : Swedish Orphan Biovitrum AB - The NEJM publishes phase 3 PEGASUS..
AQ
2021SWEDISH ORPHAN BIOVITRUM : The NEJM publishes phase 3 PEGASUS study results comparing pegc..
AQ
2021SWEDISH ORPHAN BIOVITRUM : First patient dosed in phase 3 study with avatrombopag for trea..
AQ
2021RARE DISEASE DAY 2021 : Pandemic illuminates every day social obstacles of living with a r..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the fourth quarter and full-year 2020
AQ
2021SWEDISH ORPHAN BIOVITRUM : Kineret approved in Russia for the treatment of CAPS
AQ
2021SWEDISH ORPHAN BIOVITRUM : Kineret® (anakinra) approved in Russia for the treatment of CAP..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q4 and FY 2020 results
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi showcases commitment to haemophilia community at EAHAD 202..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Favourable results for Elocta® when evaluating treatment option..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Doptelet® (avatrombopag) approved in the EU for treatment of IT..
AQ
2020FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antag..
GL
2020SWEDISH ORPHAN BIOVITRUM : Sobi appoints new Head of North America ahead of launch phase
AQ
2020SWEDISH ORPHAN BIOVITRUM : Doptelet receives positive opinion from CHMP for treatment of I..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Realising opportunities for future growth and financial update,..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Emapalumab submission in China for primary HLH
AQ
2020SWEDISH ORPHAN BIOVITRUM : Doptelet® (avatrombopag) receives positive opinion from CHMP fo..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Sobi and Apellis report positive top-line results at 48 weeks f..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Emapalumab submission in China for primary HLH
AQ
2020REALISING OPPORTUNITIES FOR FUTURE G : Sobi Capital Markets Day 2020
AQ
2020SWEDISH ORPHAN BIOVITRUM : Agenda, Sobi Capital Markets Day 2020
AQ
2020AGENDA : Sobi Capital Markets Day 2020
AQ
2020SWEDISH ORPHAN BIOVITRUM : Sobi and Apellis announce first patient dosed in potentially re..
AQ
2020SWEDISH ORPHAN BIOVITRUM : CHMP has adopted a negative opinion for emapalumab in Europe fo..
AQ
2020SWEDISH ORPHAN BIOVITRUM : The CHMP has adopted a negative opinion for emapalumab in Europ..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Strong Sobi presence at American Society of Hematology 2020 Ann..
AQ
1  2  3  4Next
Upcoming event on SWEDISH ORPHAN BIOVITRUM AB (PUBL)